TRI-ESTARYLLA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tri-estarylla, and what generic alternatives are available?
Tri-estarylla is a drug marketed by Xiromed and is included in one NDA.
The generic ingredient in TRI-ESTARYLLA is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRI-ESTARYLLA?
- What are the global sales for TRI-ESTARYLLA?
- What is Average Wholesale Price for TRI-ESTARYLLA?
Summary for TRI-ESTARYLLA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Patent Applications: | 8 |
| DailyMed Link: | TRI-ESTARYLLA at DailyMed |
US Patents and Regulatory Information for TRI-ESTARYLLA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiromed | TRI-ESTARYLLA | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 090793-001 | Jan 30, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
